A Study to Assess the Adverse Events and How Subcutaneous (SC) Injections and Intravenous (IV) Infusions of ABBV-142 Move Through the Body of Healthy Adult Participants
Completed · Phase 1 · NCT06774313
Conditions: Healthy Volunteer
At a glance
- Research payments reported, 2025
- $17,552
- U.S. investigators named
- 0
- Sites paid
- 0
- Planned or actual enrollment
- 73
About the trial
- Sponsor
- AbbVie
- Tested
- ABBV-142 (drug), ABBV-142 (drug), Placebo (drug), Placebo (drug)
- Dates
- Started 2025-01-22; completion 2026-04-08
- Results posted
- Not yet
This study is designed to assess the pharmacokinetic properties, safety, tolerability, and immunogenicity of ABBV-142 and determine whether predicted efficacious exposures can be safely achieved in humans.
From ClinicalTrials.gov, last updated 2026-05-06. Full record, eligibility and contacts (opens in a new tab)
Industry funding
AbbVie Inc. reported $17,552 in research payments for this study in 2025 (15 payments).
Products named: Venclexta
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
Sites paid to run it
- $17,552
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.